The BHP Group Ltd (ASX: BHP) share price is an interesting investment proposition to consider, given how much it has risen in recent times. In the last year, the ASX mining share has risen by a whopping 55%.

There are some great reasons why the company has gone up so much. Its operational performance has been strong, and commodity prices have been supportive of the company’s earnings performance.

Not only does the business continue to produce pleasing levels of resources, but it’s possible the company could continue to deliver for shareholders.

Let’s look at how good the latest result was from the business and what could happen next with a $10,000 investment.

Strong FY26 result

The ASX mining share recently reported its result for the 12 months to 30 June 2026.

It revealed that revenue grew by 15% to US$58.8 billion. This helped the company’s underlying operating profit (EBITDA) grow by 27% to $32.9 billion. Underlying attributable net profit increased by 30% to US$13.2 billion, while attributable profit rose by 9% US$9.8 billion.

All of this allowed the business to increase its final dividend to US 99 cents per share and the annual dividend per share was hiked to US$1.72. This full-year dividend comes to US$8.7 billion.

Copper was the key driver of its earnings growth. The average realised price rose 35% to US$5.74 per pound, helping underlying operating profit (EBITDA) rise 48% to US$18.2 billion. Global copper demand is expected to grow by 2.8% in the 2026 calendar year.

BHP expects global copper demand to grow from around 34mt per annum today to more than 50mt per annum by the 2050 calendar year.

There are multiple growth drivers for copper, including traditional economic growth (home building, electrical equipment and household appliances), the energy transition (renewables and electric vehicles) and digital (artificial intelligence and data centres).

BHP said current expectations are that copper demand associated with investment in data centres could grow around “sixfold” between 2024 and 2050, up to around 3mt per annum.

What could happen with a $10,000 investment in BHP shares?

Past performance is not a guarantee of future performance, particularly when it comes to a volatile/cyclical business like an ASX mining share.

According to CMC Invest, there have been 14 ratings on the business within the last three months, with the FY26 result giving investors a significant reason to update their views on the business.

The average price target of those ratings is $58.56, suggesting a possible decline of 13% over the next year. Even the most positive price target suggests the BHP share price will be flat in a year from now.

Given that projected decline, a $10,000 investment could drop in value to $8,700.

Therefore, experts are suggesting the BHP share price isn’t the best place to invest. Instead, investors should look for more compelling opportunities.

The post By September 2027, BHP shares could turn $10,000 into… appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Rio Tinto, PLS Group, BHP shares
• Experts name 2 ASX 200 blue chip shares to buy this week
• Are these 2 top Vanguard ETFs still worth buying today?
• ASX 200 mining shares outperform in final week of earnings season
• Could ASX shares crash? 5 questions every investor should ask now

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week in a positive fashion. The benchmark index rose 0.6% to 9,092.3 points.

Will the market be able to build on this on Monday? Here are five things to watch:

ASX 200 expected to fall

The Australian share market looks set for a poor start to the week following a subdued session on Wall Street on Friday. According to the latest SPI futures, the ASX 200 is expected to open the day 37 points or 0.4% lower. In the United States, the Dow Jones edged slightly lower, the S&P 500 fell 0.25%, and the Nasdaq dropped 0.5%.

Oil prices ease

It could be a subdued start to the week for ASX 200 energy shares Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) after oil prices eased on Friday night. According to Bloomberg, the WTI crude oil price was down 0.15% to US$83.40 a barrel and the Brent crude oil price was down 0.45% to US$88.10 a barrel. This was driven by news of some crude flows ​through the Strait of Hormuz.

Buy 4DMedical shares

4DMedical Ltd (ASX: 4DX) shares could be in the buy zone according to Bell Potter. This morning, in response to the healthcare technology company’s results, the broker has retained its speculative buy rating and $6.00 price target. It said: “4DX enters FY27 with good momentum at large hospital groups in the US. We expect on going revenue traction throughout the course of the year. Maintain Buy (Speculative) rating.”

Gold price sinks

It looks likely to be a poor start to the week for ASX 200 gold shares Capricorn Metals Ltd (ASX: CMM) and Northern Star Resources Ltd (ASX: NST) after the gold price sank on Friday night. According to CNBC, the gold futures price was down 2.9% to US$4,529.9 an ounce. Traders were selling gold in response to increasing US rate hike bets.

ASX 200 shares going ex-dividend

A number of ASX 200 shares are going ex-dividend this morning and could trade lower. Among them are health and safety products company Ansell Ltd (ASX: ANN), mineral sands company Iluka Resources Ltd (ASX: ILU), investment management company Pinnacle Investment Management Group Ltd (ASX: PNI), and rail freight company Aurizon Holdings Ltd (ASX: AZJ). The latter will be paying a 10.5 cents per share dividend to shareholders next month on 23 September.

The post 5 things to watch on the ASX 200 on Monday appeared first on The Motley Fool Australia.

More reading

• 5 superannuation mistakes that could shrink your nest egg
• Are ASX bank shares a buy in September?
• ASX 200 mining shares outperform in final week of earnings season
• Why gold stocks have regained their shine: Expert
• Could ASX shares crash? 5 questions every investor should ask now

Motley Fool contributor James Mickleboro has positions in Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Pro Medicus Ltd (ASX: PME) share price has been one of the stronger performers over the last six months, rising by 44%. It’s a valid question to ask whether Pro Medicus can rise much further.

Pro Medicus describes itself as a leading healthcare informatics company. It provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide.

It offers a leading suite of radiology information systems (RIS), picture archiving and communication system (PACS), artificial intelligence and e-health solutions.

Strong recovery

Pro Medicus suffered a huge decline last year and early this year as the market worried about what AI could mean for the company’s future. However, the market seems to be a bit more positive about the situation.

It helps that the business continues to report an impressive set of numbers with its financials.

In the FY26 result, revenue grew 22.9% to $261.7 million, underlying operating profit (EBIT) grew 24.4% to $196.1 million and underlying net profit after tax (NPAT) rose 24.1% to $144.7 million.

The company has a significant presence in the US, so changes in foreign exchange rates can impact what it reports in Australian dollars. FY26 changes in currency hurt the financials.

If currency rates hadn’t changed, revenue would have increased 28.4% to $273.5 million, underlying EBIT would have gone up 30.6% to $206 million and underlying NPAT would have risen 32.5% to $154.5 million.

The impressive profit growth allowed the company to hike its payout by 25.5% to 37 cents per Pro Medicus share.

The future looks promising considering the underlying EBIT margin rose again to 74.9% in FY26, up from 74% in FY25. It continues to win sizeable contracts at an impressive pace, which is helping drive revenue.

Its latest contract win was a seven-year A$25 million contract with Valley Health, which includes the relatively new cardiology imaging offering. In that announcement, Pro Medicus said its pipeline is strong and spans all market segments.

How much could the Pro Medicus share price rise in the next year?

According to CMC Invest, there have been 10 analyst ratings on the business within the last three months.

A price target tells us where an analyst thinks a share price could go in the next 12 months. The average price target of those 10 ratings is $220.14, according to CMC Invest, suggesting a possible rise of 21% over the next year.

The most optimistic price target is $240, suggesting a possible rise of 32%.

So, analysts are excited about the future of the business and it could still be one to watch.

The post How much could the Pro Medicus share price rise in the next year? appeared first on The Motley Fool Australia.

More reading

• Warren Buffett’s playbook: 3 cheap ASX shares that could soar up to 60%
• 3 ASX shares I’d buy for the next 15 years
• Buy, hold, sell: Pro Medicus, Fortescue, CBA shares
• ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
• Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday

Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.